Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report

Código QR

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report

Guardado en:

Detalles Bibliográficos
Autores principales:	Hiroshi Kasamatsu, Takenao Chino, Noritaka Oyama, Takakiyo Nakaya, Minoru Hasegawa
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	anti‐BP180‐NC16a autoantibody autoimmune bullous disease bullous pemphigoid dipeptidyl‐peptidase‐4 inhibitor omarigliptin Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/12a7ff4d63894838ad4218439e34b9af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment
por: Vito Di Lernia, et al.
Publicado: (2020)

Bullous pemphigoid induced by Hijama therapy (cupping)
por: Arghavan Azizpour, et al.
Publicado: (2018)

Diminished Expression of Galectin-3 Around Blisters in Bullous Pemphigoid: An Immunohistochemistry Study
por: Maryam Aghighi, et al.
Publicado: (2020)

Successful induction treatment of bullous pemphigoid using reslizumab: a case report
por: Hyo-In Rhyou, et al.
Publicado: (2021)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Si-Hang Wang, et al.
Publicado: (2021)

Case Report: Infantile Bullous Pemphigoid: Triggering by COVID-19 Is Speculative
por: Anna Rosińska-Więckowicz, et al.
Publicado: (2021)

The course of bullous pemphigoid against the background of vaccination against a new coronavirus infection (COVID-19)
por: Andrey A. Martynov, et al.
Publicado: (2021)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
por: Michele Fabrazzo, et al.
Publicado: (2021)

Mucous Membrane Pemphigoid-Associated Malignancies. Case Series and a Brief Overview of the Literature
por: Michelangelo La Placa, et al.
Publicado: (2019)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Modern features of VATS treatment of spontaneous pneumothorax as a complication of bullous lung emphysema: a systematic literature review
por: V. A. Toktokhoyev, et al.
Publicado: (2016)

The effects of Omarigliptin on promoting osteoblastic differentiation
por: Fake Liao, et al.
Publicado: (2021)

Staphylococcal Scalded Skin Syndrome and Bullous Impetigo
por: Morgan Brazel, et al.
Publicado: (2021)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
por: Nur Imanina Abdullah Thaidi, et al.
Publicado: (2020)

Bullous systemic lupus erythematosus: exceptional and challenging presentation
por: Salem Bouomrani, et al.
Publicado: (2020)

Molecular Dynamics Simulations Study of the Interactions between Human Dipeptidyl-Peptidase III and Two Substrates
por: Shitao Zhang, et al.
Publicado: (2021)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Bullous Aplasia Cutis Congenita—Description of a Novel Dermoscopic Feature
por: Aradhana Rout, et al.
Publicado: (2021)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

BP180/Collagen XVII: A Molecular View
por: Jussi Tuusa, et al.
Publicado: (2021)

Case Report: The First Reported Case of Bullous Lichen Planus-Systemic Lupus Erythematosus Overlap Syndrome
por: Yi Liu, et al.
Publicado: (2021)

Current approaches to the diagnosis of autoimmune bullous dermatoses
por: Marianna B. Drozhdina, et al.
Publicado: (2021)

Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis
por: Nehru Sai Suresh Chalichem, et al.
Publicado: (2021)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)

Case Report: Bullous Lung Disease Following COVID-19
por: Prachi Pednekar, et al.
Publicado: (2021)

Mycosis fungoides bullosa: An unusual presentation of a rare entity
por: Ahmad Nofal, MD, et al.
Publicado: (2021)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Changing Indications for Penetrating Keratoplasty in Bahrain in a Tertiary Referral Centre
por: Al-Yousuf N, et al.
Publicado: (2021)

THE PREDISPOSING FACTORS FOR MOCROBIAL KERATITIS IN PATIENTS WITH RED EYE REPORTING TO THE MILITARY HOSPITAL RAWALPINDI
por: khalid Naimat, et al.
Publicado: (2019)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
por: Gul O, et al.
Publicado: (2019)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Use of dermatoscopy in the detection of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa
por: Ruzica Jurakic Toncic, et al.
Publicado: (2018)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
por: Karyekar CS, et al.
Publicado: (2013)

Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh CJ, et al.
Publicado: (2014)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)